Dateline City:
WHITEHOUSE STATION, N.J.
Pembrolizumab monotherapy achieved 31 percent overall response rate in patients with PD-L1 positive, advanced gastric cancer
Phase 2 study to be initiated in first quarter of 2015 (KEYNOTE-059)
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--MSD, known as Merck in the United States and Canada, today announced the
first presentation of data on the investigational use of pembrolizumab
the companys anti-PD-1 therapy in PD-L1 positive, advanced gastric
cancer. The early findings presented showed an overall response rate
(confirmed and unconfirmed) of 31 percent with pembrolizumab as
monotherapy, as measured by investigator assessed, RECIST v1.1 (n=
12/39: 95% CI, 17-47).
Language:
English
Contact:
For MSDMedia:Ian McConnell, 973-901-5722orClaire Mulhearn, 908-423-7425orInvestors:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more